CanSino Biologics Inc (CJH) - Total Liabilities

Latest as of December 2025: €2.22 Billion EUR ≈ $2.60 Billion USD

Based on the latest financial reports, CanSino Biologics Inc (CJH) has total liabilities worth €2.22 Billion EUR (≈ $2.60 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CJH net assets growth trend to track the company's year-over-year net asset growth rate.

CanSino Biologics Inc - Total Liabilities Trend (2016–2025)

This chart illustrates how CanSino Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of CanSino Biologics Inc to measure how efficiently the company converts operating cash flow to free cash.

CanSino Biologics Inc Competitors by Total Liabilities

The table below lists competitors of CanSino Biologics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
American Exceptionalism Acquisition Corp. A NYSE:AEXA	USA	$20.73 Million
Three Stars NM SHG:603578	China	CN¥3.75 Billion
BENZ MINING CORP CDI/1 F:1VU0	Germany	€4.71 Million
Wuxi Hodgen Technology Co Ltd SHE:300279	China	CN¥745.71 Million
Tera Light Ltd TA:TRLT	Israel	ILA959.50 Million
China Railway Prefabricated Construction Co Ltd SHE:300374	China	CN¥3.55 Billion
Weihai Huadong Automation Co Ltd SHE:002248	China	CN¥339.03 Million
TrueLight TWO:3234	Taiwan	NT$270.56 Million

Liability Composition Analysis (2016–2025)

This chart breaks down CanSino Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CJH market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.55	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.45	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.31	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how CanSino Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for CanSino Biologics Inc (2016–2025)

The table below shows the annual total liabilities of CanSino Biologics Inc from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€2.22 Billion ≈ $2.60 Billion	-27.04%
2024-12-31	€3.05 Billion ≈ $3.56 Billion	-24.39%
2023-12-31	€4.03 Billion ≈ $4.71 Billion	-4.55%
2022-12-31	€4.22 Billion ≈ $4.94 Billion	+26.97%
2021-12-31	€3.33 Billion ≈ $3.89 Billion	+391.17%
2020-12-31	€677.22 Million ≈ $791.74 Million	+115.69%
2019-12-31	€313.98 Million ≈ $367.08 Million	+6.96%
2018-12-31	€293.56 Million ≈ $343.20 Million	+13.33%
2017-12-31	€259.03 Million ≈ $302.84 Million	+131.90%
2016-12-31	€111.70 Million ≈ $130.59 Million	--

About CanSino Biologics Inc

F:CJH Germany Drug Manufacturers - Specialty & Generic

Market Cap

$397.07 Million

€339.64 Million EUR

Market Cap Rank

#13401 Global

#1394 in Germany

Share Price

€2.56

Change (1 day)

+1.59%

52-Week Range

€2.28 - €5.95

All Time High

€45.99